<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386100</url>
  </required_header>
  <id_info>
    <org_study_id>AVT105913</org_study_id>
    <nct_id>NCT00386100</nct_id>
  </id_info>
  <brief_title>A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin</brief_title>
  <official_title>A Randomized, Parallel Group, Double-blind, Multi-center Study Comparing the Efficacy and Safety of AVANDAMET and Metformin After 80 Weeks of Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the longer-term glycemic effect of two medicines approved for
      initial treatment of type 2 diabetes. The study consists of a 2 week screening period (2
      study visits), followed by an 80 week double-blind treatment period (11 study visits). Also,
      a sub-study was included to look at changes in bone mineral density (BMD) at the lumbar
      spine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase IV, randomized, double-blind, global, multi-centre study. The study
      consisted of a 2 week screening period followed by an 80 week double-blind treatment period.
      Subjects who met all eligibility requirements were randomized in a 1:1 ratio, stratified by
      country, gender (male and female) and pre-screening HbA1c (≤9% or&gt;9) either to MET or AVM.
      When the substudy was added, a new randomization was created for the participating centers.
      Those subjects in the bone sub-study were stratified by country, gender (male, premenopausal
      female, and postmenopausal female), pre-screening HbA1c (i.e., ≤9%; &gt;9%), and either to MET
      or AVM.

      At randomization, Visit 3 (Week 0), subjects were initiated at Dose Level 1. Treatment with
      AVM was initiated at a dose of 4 mg/500 mg and titrated up to a maximum total daily dose of
      AVM 8 mg/2000 mg. Treatment with MET therapy was initiated at a dose of 500 mg and titrated
      up to a maximum daily dose of 2000mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Week 80</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for serum HbA1c measurements. Change from baseline was calculated as the Week 80 value minus the baseline value. Last observation carried forward (LOCF) was not used for this analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HbA1c at Week 80</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for serum Hb1AC measurements. Change from baseline was calculated as the Week 80 value minus the baseline value, with LOCF from Week 32 for withdrawn participants or missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving HbA1c &lt;=6.5% and &lt;7% at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Blood was taken for serum Hb1AC measurements. Hb1AC responders were described as participants having achieved Hb1AC &lt;=6% and &lt;7% at Week 80 with LOCF from Week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline at Week 80</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for serum FPG measurements. Change from baseline was calculated as the Week 80 value minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 80</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for serum FPG measurements. Change from baseline was calculated as the Week 80 value minus the baseline value with LOCF from Week 32 for withdrawn participants or missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving FPG &lt;=6 mmol/L (110 mg/dL) and &lt;=7 mmol/L (126 mg/dL) at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Blood was taken for serum FPG measurements. FPG responders were described as participants having achieved FPG &lt;=6 mmol/L (110 mg/dL) and &lt;7 mmol/L (126 mg/dL) Hb1AC at Week 80 with LOCF from Week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Treatment Failure</measure>
    <time_frame>Randomization to treatment failure (up to Week 80)</time_frame>
    <description>Treatment failure was defined as an HbA1c level &gt;= 7% after Week 32 or withdrawal due to insufficient therapeutic effect (ITE) at any time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, and Triglycerides at Week 80</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for measurement of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Percent change from baseline at Week 80 was based on log transformed data. Geometric mean, GM; standard error, SE. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Adiponectin at Week 80 (United States [US] and Mexico Subset of Participants )</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for measurement of adiponectin. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C-reactive Protein (CRP) at Week 80 (US and Mexico Subset of Participants)</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for measurement of CRP. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Free Fatty Acids (FFA) From Baseline at Week 80 (US and Mexico Subset of Participants).</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for measurement of FFA. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin From Baseline at Week 80 (US and Mexico Subset of Participants)</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for fasting insulin measurements. Change from baseline was calculated as the Week 80 value minus the baseline value, with LOCF from Week 32 for withdrawn participants or missing values. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-peptide From Baseline at Week 80 (US and Mexico Subset of Participants)</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for C-peptide measurements. Change from baseline was calculated as the Week 80 value minus the baseline value with LOCF from Week 32 for withdrawn participants or missing values. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in in HOMA-S and HOMA-B to Week 80 (US and Mexico Subset of Participants)</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for measurement of homeostasis model assessment for insulin sensitivity (HOMA-S) and beta-cell function (HOMA-B). Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only. GM, geometric mean; SE, standard error.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of Delta-cell Function as Estimated by the Ratio deltaI/deltaG</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>The ratio Delta I/Delta G is calculated based on the oral glucose tolerance test (OGTT), where Delta I = (30 minute immunoreactive insulin minus 0 minute immunoreactive insulin) and Delta G = (30 minute plasma glucose minus 0 minute plasma glucose). The 0 minute values are fasting insulin and glucose; the 30 minute values are taken 30 minutes after the oral glucose challenge. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants at Final Dose Level</measure>
    <time_frame>Baseline to Week 80 or withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mass Density (BMD) at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100%. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Hip BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Trochanter BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Distal Radius BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Calcium at Weeks 12, 32, 56, and 80</measure>
    <time_frame>Baseline and Weeks 12, 32, 56, and 80</time_frame>
    <description>Blood was taken for measurement of serum calcium. Percent change from baseline was based on log transformed data. Geometric mean, GM; standard error, SE. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Intact Parathyroid Hormone at Week 80</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for measurement of intact parathyroid hormone. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in 25-hydroxy Vitamin D at Week 80</measure>
    <time_frame>Baseline and Week 80</time_frame>
    <description>Blood was taken for measurement of 25-hydroxy vitamin D. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Estradiol at Weeks 20, 56, and 80</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>Blood was taken for measurement of estradiol. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of female participants in the bone study only. n is the number of evaluable participants, which is the number of female participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C-terminal Telopeptide (CTX) at Weeks 20, 56, and 80</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>Blood was taken for measurement of CTX. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Procollagen Type-1 N-propeptide (P1NP) at Weeks 20, 56, and 80</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>Blood was taken for measurement of P1NP. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Alkaline Phosphatase (BSAP) at Weeks 20, 56, and 80</measure>
    <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
    <description>Blood was taken for measurement of BSAP. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">688</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avandamet (Rosiglitazone maleate/metformin hydrochloride)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avandamet 6 mg/1500 mg (ttd)</intervention_name>
    <description>One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal</description>
    <arm_group_label>Avandamet (Rosiglitazone maleate/metformin hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avandamet 4 mg/1000 mg (ttd)</intervention_name>
    <description>One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.</description>
    <arm_group_label>Avandamet (Rosiglitazone maleate/metformin hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avandamet 2 mg/500 mg (ttd)</intervention_name>
    <description>one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.</description>
    <arm_group_label>Avandamet (Rosiglitazone maleate/metformin hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avandamet 8 mg/ 2000 mg (ttd)</intervention_name>
    <description>Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.</description>
    <arm_group_label>Avandamet (Rosiglitazone maleate/metformin hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 500 mg (ttd)</intervention_name>
    <description>One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1000 mg (ttd)</intervention_name>
    <description>One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1500 mg (ttd)</intervention_name>
    <description>One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 2000 mg (ttd)</intervention_name>
    <description>Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject provides written informed consent.

          -  The subject is male or female and 18 to 75 years of age at the time of pre-screening.

          -  The subject has an established clinical diagnosis of type 2 diabetes according to
             recommended guidelines (e.g., American Diabetes Association, International Diabetes
             Federation, World Health Organization, Canadian Diabetes Association, or American
             Association of Clinical Endocrinologists).

          -  The subject is currently treated with diet and exercise, and has not taken more than 2
             weeks of an anti-diabetic monotherapy or insulin in the past 6 months.

          -  The subject has a BMI &gt;25 kg/m2 at pre-screening.

          -  The subject has a Quest HbA1c 7.5% to 10.5% at pre-screening.

          -  The subject has a fasting capillary blood glucose 126 mg/dL (7mmol/L), as measured by
             the site staff at week 0.

          -  If the subject is a pre-menopausal female of child-bearing potential, she agrees to
             practice acceptable contraceptive measures (e.g. oral birth control pills, Norplant,
             Depo-Provera, an intrauterine device (IUD), a diaphragm with spermicide or a condom
             with spermicide, or abstinence) at least 1 month before screening, during the study,
             and for 30 days after the last dose of study medication is taken

          -  The subject is able and willing to perform self-monitoring of blood glucose as
             specified in this protocol.

        Exclusion Criteria:

          -  The subject has taken an oral anti-diabetic monotherapy or insulin for more than 14
             days in the past 6 months.

          -  The subject has presence of clinically significant renal or hepatic disease (serum
             creatinine 1.5 mg/dL (132.6 mol/L) for males and 1.4 mg/dL (123.8 mol/L) for females):
             ALT, AST, total bilirubin, or alkaline phosphatase &gt;2.5 times the upper limit of the
             normal (ULN) reference range.

          -  The subject has anemia defined by hemoglobin concentration &lt;11g/dL (110g/L) for males
             or &lt;10g/dL (100g/L) for females.

          -  Presence of unstable or severe angina, coronary insufficiency or New York Heart
             Association (NYHA) class III-IV or any congestive heart failure requiring
             pharmacologic treatment.

          -  The subject has systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;90 mmHg

          -  The subject has a chronic disease requiring intermittent or chronic treatment with
             oral, intravenous, or intra-articular corticosteroids (i.e., only use of topical,
             inhaled or nasal corticosteroids is permitted).

          -  The subject has acute or chronic metabolic acidosis or a history of diabetic
             ketoacidosis.

          -  The subject has a clinically significant abnormality which in the judgment of the
             investigator makes the subject unsuitable for inclusion in the study (e.g., physical
             examination, laboratory tests, or electrocardiogram, etc).

          -  The subject has used an investigational agent within 30 days or 5 half-lives
             (whichever was longer) prior to pre-screening.

          -  The subject is a female who is lactating, pregnant, or planned to become pregnant.

          -  The subject has a prior history of severe edema or a medically serious fluid related
             event (e.g., heart failure).

          -  The subject has a history of macular edema.

          -  The subject has significant hypersensitivity (e.g., difficulty swallowing, difficulty
             breathing, and tachycardia or skin reaction) to TZDs, biguanides, or compounds with
             similar chemical structures.

          -  The subject has a diagnosis of cancer (other than squamous, basal cell, or cervical
             cancer in-situ) in the past 3 years and is receiving treatment for cancer.

          -  The subject has a history or suspicion of drug abuse or alcohol abuse within the last
             6 months.

          -  The subject is known to have severe lactose intolerance.

          -  The subject is not willing to comply with visits and procedures described in the
             protocol.

          -  The subject has a disease that may affect bone turnover including, but not limited to:
             Paget's disease, hypercalcemia, hypocalcemia, hyperparathyroidism, hyperthyroidism,
             osteomalacia, metastatic bone disease

          -  The subject has a weight of greater than 300 lbs (136.4 kg).

          -  The subject has received treatment with bisphosphonates (≥1 month cumulative treatment
             within the last 12 months) or fluoride (dose greater than 10mg/day within the previous
             5 years).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kahului</city>
        <state>Hawaii</state>
        <zip>96732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407-3799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Excelsior Springs</city>
        <state>Missouri</state>
        <zip>64024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pahrump</city>
        <state>Nevada</state>
        <zip>89048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Canal Fulton</city>
        <state>Ohio</state>
        <zip>44614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mogadore</city>
        <state>Ohio</state>
        <zip>44260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wandsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oregon City</city>
        <state>Oregon</state>
        <zip>97045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clairton</city>
        <state>Pennsylvania</state>
        <zip>15205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coatsville</city>
        <state>Pennsylvania</state>
        <zip>19320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sewickley</city>
        <state>Pennsylvania</state>
        <zip>15143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Chester</city>
        <state>Pennsylvania</state>
        <zip>19382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pelzer</city>
        <state>South Carolina</state>
        <zip>29669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gig Harbor</city>
        <state>Washington</state>
        <zip>98335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Graham</city>
        <state>Washington</state>
        <zip>98338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aries</city>
        <state>Buenos Aires</state>
        <zip>C1425AWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>C1416DRJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>B1704ETD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1155ADP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdova</state>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1117ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60120-021</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74110-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasília</city>
        <zip>71625-009</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <zip>E2A 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 3T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <zip>K7A 4W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-749</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>139-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon, Kyonggi-do</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uijeongbu-si, Kyonggi-do</city>
        <zip>480-130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California Norte</state>
        <zip>22320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pachuca</city>
        <state>Hidalgo</state>
        <zip>42039</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lahore</city>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marikina City</city>
        <zip>1810</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1108</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan Hsien</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Pakistan</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients. Diabetes Obes Metab. 2011 Nov;13(11):1036-46. doi: 10.1111/j.1463-1326.2011.01461.x.</citation>
    <PMID>21682834</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <results_first_submitted>July 8, 2010</results_first_submitted>
  <results_first_submitted_qc>March 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2011</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fasting Plasma Glucose</keyword>
  <keyword>Dual energy X ray absorptiometry (DXA)</keyword>
  <keyword>Drug-naive</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>AVT105913</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVT105913</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVT105913</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVT105913</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVT105913</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVT105913</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVT105913</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
        </group>
        <group group_id="P2">
          <title>Avandamet</title>
          <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="348"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive study medication</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bone mass density (BMD) loss &gt;6%</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>BMD &lt;2.5</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consecutive elevated Hba1C</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Visit 11 DXA showed excessive bone loss</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory findings</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant's concern due to CPK levels</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moving out of state</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excessive bone loss vs. baseline value</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Didn't meet entry criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant's PCP wanted to stop drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Osteoporosis findings on Visit 2 DXA</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bad metabolic control &amp; patient security</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bone loss by DXA bone scan</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>DBP 93 mmHg at randomization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>7.6% bone loss</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Osteoporosis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive pregnancy test</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out of country for 5 months</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hb1Ac &gt;8%</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
        </group>
        <group group_id="B2">
          <title>Avandamet</title>
          <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="334"/>
            <count group_id="B2" value="344"/>
            <count group_id="B3" value="678"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The Safety Population, comprised of all participants who were randomized and received at least one dose of the study medication, was used for all baseline characteristics.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="10.49"/>
                    <measurement group_id="B2" value="51.5" spread="10.52"/>
                    <measurement group_id="B3" value="51.1" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African America/African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian – Central/South Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian – East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian – Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian – South East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White – Arabic/North African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White – White/Caucasian/European</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <description>The Safety Population, comprised of all participants who were randomized and received at least one dose of the study medication, was used for all baseline characteristics.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.570" spread="3.2671"/>
                    <measurement group_id="B2" value="2.293" spread="3.0774"/>
                    <measurement group_id="B3" value="2.429" spread="3.1729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HbA1c at Week 80</title>
        <description>Blood was taken for serum Hb1AC measurements. Change from baseline was calculated as the Week 80 value minus the baseline value, with LOCF from Week 32 for withdrawn participants or missing values.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF: a subset of the ITT Population with LOCF starting at Week 32. Only participants with assessment(s) at Week 32 or later were included in this population. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HbA1c at Week 80</title>
          <description>Blood was taken for serum Hb1AC measurements. Change from baseline was calculated as the Week 80 value minus the baseline value, with LOCF from Week 32 for withdrawn participants or missing values.</description>
          <population>Week 32 Evaluable Population with LOCF: a subset of the ITT Population with LOCF starting at Week 32. Only participants with assessment(s) at Week 32 or later were included in this population. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="0.898"/>
                    <measurement group_id="O2" value="8.66" spread="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="0.070"/>
                    <measurement group_id="O2" value="-1.91" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustment for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, region, gender, and baseline value with LOCF from Week 32 for withdrawn participants or missing values</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.669</ci_lower_limit>
            <ci_upper_limit>-0.305</ci_upper_limit>
            <estimate_desc>AVM mean change from baseline minus MET mean change from baseline based on ANCOVA model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Week 80</title>
        <description>Blood was taken for serum HbA1c measurements. Change from baseline was calculated as the Week 80 value minus the baseline value. Last observation carried forward (LOCF) was not used for this analysis.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who were randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value. Only evaluable participants, defined as the number of participants with a baseline and at least one post baseline assessment, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 80</title>
          <description>Blood was taken for serum HbA1c measurements. Change from baseline was calculated as the Week 80 value minus the baseline value. Last observation carried forward (LOCF) was not used for this analysis.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who were randomized, received at least one dose of study medication, and had both a baseline and at least one on-therapy value. Only evaluable participants, defined as the number of participants with a baseline and at least one post baseline assessment, were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.64" spread="0.053"/>
                    <measurement group_id="O2" value="8.64" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.073"/>
                    <measurement group_id="O2" value="-1.85" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustment for multiple comparisons</p_value_desc>
            <method>Repeated measures analysis</method>
            <method_desc>Repeated measures analysis with terms for baseline, region, treatment, gender, time, and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
            <estimate_desc>AVM mean change from baseline minus MET mean change from baseline based on repeated measures analysis model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving HbA1c &lt;=6.5% and &lt;7% at Week 80</title>
        <description>Blood was taken for serum Hb1AC measurements. Hb1AC responders were described as participants having achieved Hb1AC &lt;=6% and &lt;7% at Week 80 with LOCF from Week 32.</description>
        <time_frame>Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HbA1c &lt;=6.5% and &lt;7% at Week 80</title>
          <description>Blood was taken for serum Hb1AC measurements. Hb1AC responders were described as participants having achieved Hb1AC &lt;=6% and &lt;7% at Week 80 with LOCF from Week 32.</description>
          <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;7%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <p_value_desc>Hb1AC &lt;= 6.5%</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic reggression with terms for treatment, region, gender, and baseline Hb1AC with LOCF from Week 32.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
            <estimate_desc>Odds of having an HbA1c &lt;= 6.5% at Week 80 on Avandamet compared to Metformin.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hb1AC &lt; 7%</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic reggression with terms for treatment, region, gender, and baseline Hb1AC with LOCF from Week 32</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>3.81</ci_upper_limit>
            <estimate_desc>Odds of having an HbA1c &lt;7% at Week 80 on Avandamet compared to Metformin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline at Week 80</title>
        <description>Blood was taken for serum FPG measurements. Change from baseline was calculated as the Week 80 value minus the baseline value.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>ITT Population. Only evaluable participants, defined as the number of participants with a baseline and at least one post baseline assessment, were analyzed. Last observation carried forward (LOCF) was not used for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline at Week 80</title>
          <description>Blood was taken for serum FPG measurements. Change from baseline was calculated as the Week 80 value minus the baseline value.</description>
          <population>ITT Population. Only evaluable participants, defined as the number of participants with a baseline and at least one post baseline assessment, were analyzed. Last observation carried forward (LOCF) was not used for this analysis.</population>
          <units>millimoles per Liter (mmol/l)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.52" spread="0.184"/>
                    <measurement group_id="O2" value="10.17" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="0.147"/>
                    <measurement group_id="O2" value="-3.41" spread="0.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Repeated measures analysis</method>
            <method_desc>Terms for baseline, region, treatment, pre-screening Hb1Ac strata, gender, time, and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>-0.77</ci_upper_limit>
            <estimate_desc>AVM mean change from baseline minus MET mean change from baseline based on repeated measures analysis model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 80</title>
        <description>Blood was taken for serum FPG measurements. Change from baseline was calculated as the Week 80 value minus the baseline value with LOCF from Week 32 for withdrawn participants or missing values.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 80</title>
          <description>Blood was taken for serum FPG measurements. Change from baseline was calculated as the Week 80 value minus the baseline value with LOCF from Week 32 for withdrawn participants or missing values.</description>
          <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.37" spread="3.268"/>
                    <measurement group_id="O2" value="10.13" spread="2.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" spread="3.165"/>
                    <measurement group_id="O2" value="-3.39" spread="2.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment, region, gender, pre-screening Hb1Ac strata, and baseline with LOCF from Week 32 for withdrawn participants or missing values</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.425</ci_lower_limit>
            <ci_upper_limit>-0.710</ci_upper_limit>
            <estimate_desc>AVM mean change from baseline minus MET mean change from baseline based on ANCOVA model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving FPG &lt;=6 mmol/L (110 mg/dL) and &lt;=7 mmol/L (126 mg/dL) at Week 80</title>
        <description>Blood was taken for serum FPG measurements. FPG responders were described as participants having achieved FPG &lt;=6 mmol/L (110 mg/dL) and &lt;7 mmol/L (126 mg/dL) Hb1AC at Week 80 with LOCF from Week 32.</description>
        <time_frame>Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving FPG &lt;=6 mmol/L (110 mg/dL) and &lt;=7 mmol/L (126 mg/dL) at Week 80</title>
          <description>Blood was taken for serum FPG measurements. FPG responders were described as participants having achieved FPG &lt;=6 mmol/L (110 mg/dL) and &lt;7 mmol/L (126 mg/dL) Hb1AC at Week 80 with LOCF from Week 32.</description>
          <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FPG &lt;=6.1 mmol/l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FPG &lt;=7.0 mmol/l</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>FPG &lt;=6.1 mmol/l</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Terms for treatment, region, gender, pre-screening Hb1Ac strata, and baseline with LOCF from Week 32.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.94</ci_lower_limit>
            <ci_upper_limit>6.81</ci_upper_limit>
            <estimate_desc>Odds of having an FPG &lt;=6.1 mmol/l at Week 80 on Avandamet compared to Metformin</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>FPG &lt;=7 mmol/l</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Terms for treatment, region, gender, pre-screening Hb1Ac, and baseline with LOCF from Week 32.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.25</ci_lower_limit>
            <ci_upper_limit>4.92</ci_upper_limit>
            <estimate_desc>Odds of having an FPG &lt;=7 mmol/l at Week 80 on Avandamet compared to Metformin</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Treatment Failure</title>
        <description>Treatment failure was defined as an HbA1c level &gt;= 7% after Week 32 or withdrawal due to insufficient therapeutic effect (ITE) at any time.</description>
        <time_frame>Randomization to treatment failure (up to Week 80)</time_frame>
        <population>ITT Population. Only evaluable participants, defined as the number of subjects with a baseline and at least one post baseline assessment, were analyzed. Last observation carried forward (LOCF) was not used for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Treatment Failure</title>
          <description>Treatment failure was defined as an HbA1c level &gt;= 7% after Week 32 or withdrawal due to insufficient therapeutic effect (ITE) at any time.</description>
          <population>ITT Population. Only evaluable participants, defined as the number of subjects with a baseline and at least one post baseline assessment, were analyzed. Last observation carried forward (LOCF) was not used for this analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox proportional hazard regression with terms for treatment, region, baseline Hb1Ac strata, and gender</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, and Triglycerides at Week 80</title>
        <description>Blood was taken for measurement of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Percent change from baseline at Week 80 was based on log transformed data. Geometric mean, GM; standard error, SE. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 evaluable population with LOCF from Week 32. n is the number of evaluable participants, which is defined as the number of participants with a value at baseline and at the specified visit for the parameter of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, and Triglycerides at Week 80</title>
          <description>Blood was taken for measurement of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Percent change from baseline at Week 80 was based on log transformed data. Geometric mean, GM; standard error, SE. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 32 evaluable population with LOCF from Week 32. n is the number of evaluable participants, which is defined as the number of participants with a value at baseline and at the specified visit for the parameter of interest.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% change + SE, Total cholesterol, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.615"/>
                    <measurement group_id="O2" value="4.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change, Total cholesterol, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89"/>
                    <measurement group_id="O2" value="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change - SE, Total cholesterol, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.140"/>
                    <measurement group_id="O2" value="1.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change + SE, LDL cholesterol, n=248, 252</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.933"/>
                    <measurement group_id="O2" value="3.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change, LDL cholesterol, n=248, 252</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.11"/>
                    <measurement group_id="O2" value="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change - SE, LDL cholesterol, n=248, 252</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.228"/>
                    <measurement group_id="O2" value="-1.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change + SE, HDL cholesterol, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.761"/>
                    <measurement group_id="O2" value="9.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change, HDL cholesterol, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.60"/>
                    <measurement group_id="O2" value="8.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change - SE, HDL cholesterol, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.453"/>
                    <measurement group_id="O2" value="7.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change + SE, triglycerides, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.696"/>
                    <measurement group_id="O2" value="-2.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change, triglycerides, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.330"/>
                    <measurement group_id="O2" value="-4.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% change - SE, triglycerides, n=258, 265</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.893"/>
                    <measurement group_id="O2" value="-7.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Total cholesterol. No adjustment for multiple comparisons. Log transformed</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>5.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.522</ci_lower_limit>
            <ci_upper_limit>9.526</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>LDL cholesterol. No adjustment for multiple comparisons. Log transformed</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>8.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.486</ci_lower_limit>
            <ci_upper_limit>15.304</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>HDL cholesterol. No adjustment for multiple comparison. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>2.580</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.232</ci_lower_limit>
            <ci_upper_limit>5.470</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.835</p_value>
            <p_value_desc>Triglycerides. No adjustment for multiple comparisons. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>0.743</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.056</ci_lower_limit>
            <ci_upper_limit>8.035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Adiponectin at Week 80 (United States [US] and Mexico Subset of Participants )</title>
        <description>Blood was taken for measurement of adiponectin. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as the number of participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Adiponectin at Week 80 (United States [US] and Mexico Subset of Participants )</title>
          <description>Blood was taken for measurement of adiponectin. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
          <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as the number of participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change from baseline + SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.58"/>
                    <measurement group_id="O2" value="139.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.96"/>
                    <measurement group_id="O2" value="128.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline - SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61"/>
                    <measurement group_id="O2" value="118.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustment for multiple comparisons. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>102.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.23</ci_lower_limit>
            <ci_upper_limit>128.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in C-reactive Protein (CRP) at Week 80 (US and Mexico Subset of Participants)</title>
        <description>Blood was taken for measurement of CRP. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as the number of participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in C-reactive Protein (CRP) at Week 80 (US and Mexico Subset of Participants)</title>
          <description>Blood was taken for measurement of CRP. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
          <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as the number of participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change from baseline + SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.49"/>
                    <measurement group_id="O2" value="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.63"/>
                    <measurement group_id="O2" value="-17.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline - SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.59"/>
                    <measurement group_id="O2" value="-21.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1380</p_value>
            <p_value_desc>No adjustment for multiple comparisons. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-8.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.04</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Free Fatty Acids (FFA) From Baseline at Week 80 (US and Mexico Subset of Participants).</title>
        <description>Blood was taken for measurement of FFA. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Free Fatty Acids (FFA) From Baseline at Week 80 (US and Mexico Subset of Participants).</title>
          <description>Blood was taken for measurement of FFA. Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
          <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change from baseline + SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.353"/>
                    <measurement group_id="O2" value="1.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40"/>
                    <measurement group_id="O2" value="-2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline - SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.657"/>
                    <measurement group_id="O2" value="-7.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0342</p_value>
            <p_value_desc>No adjustment for multiple comparisons. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-11.308</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.617</ci_lower_limit>
            <ci_upper_limit>-0.899</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin From Baseline at Week 80 (US and Mexico Subset of Participants)</title>
        <description>Blood was taken for fasting insulin measurements. Change from baseline was calculated as the Week 80 value minus the baseline value, with LOCF from Week 32 for withdrawn participants or missing values. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin From Baseline at Week 80 (US and Mexico Subset of Participants)</title>
          <description>Blood was taken for fasting insulin measurements. Change from baseline was calculated as the Week 80 value minus the baseline value, with LOCF from Week 32 for withdrawn participants or missing values. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
          <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>picomoles per Liter (pmol/l)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="9.18"/>
                    <measurement group_id="O2" value="-35.2" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <p_value_desc>No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, region, gender, pre-screening HbA1c strata, and baseline.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-33.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.666</ci_lower_limit>
            <ci_upper_limit>-0.99</ci_upper_limit>
            <estimate_desc>AVM mean change from baseline minus MET mean change from baseline based on ANCOVA model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-peptide From Baseline at Week 80 (US and Mexico Subset of Participants)</title>
        <description>Blood was taken for C-peptide measurements. Change from baseline was calculated as the Week 80 value minus the baseline value with LOCF from Week 32 for withdrawn participants or missing values. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-peptide From Baseline at Week 80 (US and Mexico Subset of Participants)</title>
          <description>Blood was taken for C-peptide measurements. Change from baseline was calculated as the Week 80 value minus the baseline value with LOCF from Week 32 for withdrawn participants or missing values. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
          <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.244" spread="0.0518"/>
                    <measurement group_id="O2" value="-0.473" spread="0.0502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>No adjustment for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with terms for treatment, region, gender, pre-screening HbA1c strata, and baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.229</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.359</ci_lower_limit>
            <ci_upper_limit>-0.099</ci_upper_limit>
            <estimate_desc>AVM mean change from baseline minus MET mean change from baseline based on ANCOVA model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in in HOMA-S and HOMA-B to Week 80 (US and Mexico Subset of Participants)</title>
        <description>Blood was taken for measurement of homeostasis model assessment for insulin sensitivity (HOMA-S) and beta-cell function (HOMA-B). Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only. GM, geometric mean; SE, standard error.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in in HOMA-S and HOMA-B to Week 80 (US and Mexico Subset of Participants)</title>
          <description>Blood was taken for measurement of homeostasis model assessment for insulin sensitivity (HOMA-S) and beta-cell function (HOMA-B). Percent change from baseline at Week 80 was based on log transformed data. This outcome measure was analyzed for a subset of participants in the US and Mexico only. GM, geometric mean; SE, standard error.</description>
          <population>Week 32 Evaluable Population with LOCF for US and Mexico subset. Only evaluable participants, defined as participants with a value at baseline and at the specified visit for the parameter of interest, were analyzed.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change HOMA-B + SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.25"/>
                    <measurement group_id="O2" value="92.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change HOMA-B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.85"/>
                    <measurement group_id="O2" value="83.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change HOMA-B - SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.92"/>
                    <measurement group_id="O2" value="74.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change HOMA-S + SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.13"/>
                    <measurement group_id="O2" value="63.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change HOMA-S</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.65"/>
                    <measurement group_id="O2" value="55.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change HOMA-S - SE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49"/>
                    <measurement group_id="O2" value="47.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7148</p_value>
            <p_value_desc>HOMA-B. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>2.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.87</ci_lower_limit>
            <ci_upper_limit>16.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>HOMA-S. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with log (value) minus log (baseline [BL]) as dependent variable. Terms for treatment, region, gender, pre-screening HbA1c strata, and log (BL)</method_desc>
            <param_type>percent difference from metformin</param_type>
            <param_value>31.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.82</ci_lower_limit>
            <ci_upper_limit>49.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slope of Delta-cell Function as Estimated by the Ratio deltaI/deltaG</title>
        <description>The ratio Delta I/Delta G is calculated based on the oral glucose tolerance test (OGTT), where Delta I = (30 minute immunoreactive insulin minus 0 minute immunoreactive insulin) and Delta G = (30 minute plasma glucose minus 0 minute plasma glucose). The 0 minute values are fasting insulin and glucose; the 30 minute values are taken 30 minutes after the oral glucose challenge. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants from US and Mexico sites with a value at baseline and at the specified visit, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Slope of Delta-cell Function as Estimated by the Ratio deltaI/deltaG</title>
          <description>The ratio Delta I/Delta G is calculated based on the oral glucose tolerance test (OGTT), where Delta I = (30 minute immunoreactive insulin minus 0 minute immunoreactive insulin) and Delta G = (30 minute plasma glucose minus 0 minute plasma glucose). The 0 minute values are fasting insulin and glucose; the 30 minute values are taken 30 minutes after the oral glucose challenge. This outcome measure was analyzed for a subset of participants in the US and Mexico only.</description>
          <population>Week 32 Evaluable Population with LOCF. Only evaluable participants, defined as participants from US and Mexico sites with a value at baseline and at the specified visit, were analyzed.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.23" spread="59.706"/>
                    <measurement group_id="O2" value="-5.38" spread="55.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.319</p_value>
            <method>Repeated measures analysis</method>
            <method_desc>Repeated measures analysis with terms for baseline, region, treatment, gender, pre-screening Hb1AC, time, and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>80.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.035</ci_lower_limit>
            <ci_upper_limit>240.744</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants at Final Dose Level</title>
        <time_frame>Baseline to Week 80 or withdrawal</time_frame>
        <population>Safety population. This population consisted of all participants who were randomized and received at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants at Final Dose Level</title>
          <population>Safety population. This population consisted of all participants who were randomized and received at least one dose of the study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose level 1 AVM 4 mg/500 mg, MET 500 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose level 2 AVM 4 mg/1000 mg, MET 1000 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose level 3 AVM 6 mg/1500 mg, MET 1500 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose level 4 AVM 8 mg/2000 mg, MET 2000 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mass Density (BMD) at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
        <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100%. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mass Density (BMD) at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
          <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100%. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall population, Week 80, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.54"/>
                    <measurement group_id="O2" value="0.1" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 56, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.45"/>
                    <measurement group_id="O2" value="0.3" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 20, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.41"/>
                    <measurement group_id="O2" value="0.5" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 80, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.81"/>
                    <measurement group_id="O2" value="1.0" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 56, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.61"/>
                    <measurement group_id="O2" value="0.7" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 20, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.63"/>
                    <measurement group_id="O2" value="-0.2" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 80, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="0.77"/>
                    <measurement group_id="O2" value="0.2" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 56, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.70"/>
                    <measurement group_id="O2" value="0.3" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 20, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.52"/>
                    <measurement group_id="O2" value="1.2" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 80, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.01"/>
                    <measurement group_id="O2" value="-0.7" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 56, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.88"/>
                    <measurement group_id="O2" value="0.2" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 20, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.75"/>
                    <measurement group_id="O2" value="0.5" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 80, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="1.22"/>
                    <measurement group_id="O2" value="0" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 56, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="1.09"/>
                    <measurement group_id="O2" value="-0.1" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 20, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.73"/>
                    <measurement group_id="O2" value="-1.1" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>Overall population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <p_value_desc>Overall population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0308</p_value>
            <p_value_desc>Overall population, Week 20. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0954</p_value>
            <p_value_desc>Male population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <p_value_desc>Female population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Female population, Week 20. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2363</p_value>
            <p_value_desc>Premenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0161</p_value>
            <p_value_desc>Postmenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0338</p_value>
            <p_value_desc>Postmenopausal female population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>Postmenopausal female population, Week 20. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Hip BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
        <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Hip BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
          <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall population, Week 80, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.35"/>
                    <measurement group_id="O2" value="-1.5" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 56, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.31"/>
                    <measurement group_id="O2" value="-1.2" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 20, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.24"/>
                    <measurement group_id="O2" value="-0.4" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 80, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.46"/>
                    <measurement group_id="O2" value="-1.0" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 56, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.41"/>
                    <measurement group_id="O2" value="-0.8" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 20, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.35"/>
                    <measurement group_id="O2" value="-0.3" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 80, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.60"/>
                    <measurement group_id="O2" value="-1.8" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 56, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.52"/>
                    <measurement group_id="O2" value="-1.4" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 20, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.37"/>
                    <measurement group_id="O2" value="-0.6" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 80, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.71"/>
                    <measurement group_id="O2" value="-0.9" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 56, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.69"/>
                    <measurement group_id="O2" value="-1.6" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 20, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.48"/>
                    <measurement group_id="O2" value="0.0" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 80, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.97"/>
                    <measurement group_id="O2" value="-2.3" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 56, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.81"/>
                    <measurement group_id="O2" value="-1.5" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 20, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.57"/>
                    <measurement group_id="O2" value="-0.6" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Overall population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0110</p_value>
            <p_value_desc>Overall population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0618</p_value>
            <p_value_desc>Overall population, Week 20. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0110</p_value>
            <p_value_desc>Male population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0272</p_value>
            <p_value_desc>Male population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0337</p_value>
            <p_value_desc>Male population, Week 20. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <p_value_desc>Female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0570</p_value>
            <p_value_desc>Female population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0296</p_value>
            <p_value_desc>Premenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0155</p_value>
            <p_value_desc>Premenopausal female population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5870</p_value>
            <p_value_desc>Premenopausal female population, Week 20. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1854</p_value>
            <p_value_desc>Postmenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Trochanter BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
        <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Trochanter BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
          <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall population, Week 80, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.54"/>
                    <measurement group_id="O2" value="-2.1" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 56, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.49"/>
                    <measurement group_id="O2" value="-1.7" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 20, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.35"/>
                    <measurement group_id="O2" value="-0.6" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 80, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.69"/>
                    <measurement group_id="O2" value="-0.4" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 56, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.67"/>
                    <measurement group_id="O2" value="-0.5" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 20, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.55"/>
                    <measurement group_id="O2" value="-0.2" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 80, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.93"/>
                    <measurement group_id="O2" value="-2.6" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 56, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.80"/>
                    <measurement group_id="O2" value="-2.1" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 20, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.52"/>
                    <measurement group_id="O2" value="-0.8" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 80, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.18"/>
                    <measurement group_id="O2" value="-1.4" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 56, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.94"/>
                    <measurement group_id="O2" value="-2.6" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 20, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.71"/>
                    <measurement group_id="O2" value="0.0" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 80, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.45"/>
                    <measurement group_id="O2" value="-3.6" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 56, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.25"/>
                    <measurement group_id="O2" value="-2.2" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 20, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.76"/>
                    <measurement group_id="O2" value="-1.0" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>Overall population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0134</p_value>
            <p_value_desc>Overall population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0967</p_value>
            <p_value_desc>Overall population, Week 20. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0512</p_value>
            <p_value_desc>Male population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0330</p_value>
            <p_value_desc>Female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0547</p_value>
            <p_value_desc>Female population, Week 56. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0613</p_value>
            <p_value_desc>Premenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1369</p_value>
            <p_value_desc>Postmenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
        <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
          <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall population, Week 80, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.39"/>
                    <measurement group_id="O2" value="-1.4" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 56, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.39"/>
                    <measurement group_id="O2" value="-0.8" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 20, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.36"/>
                    <measurement group_id="O2" value="-0.2" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 80, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.66"/>
                    <measurement group_id="O2" value="-2.2" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 56, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.64"/>
                    <measurement group_id="O2" value="-1.3" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 20, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.60"/>
                    <measurement group_id="O2" value="-0.7" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 80, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.56"/>
                    <measurement group_id="O2" value="-1.2" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 56, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.55"/>
                    <measurement group_id="O2" value="-0.5" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 20, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.49"/>
                    <measurement group_id="O2" value="-0.2" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 80, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.73"/>
                    <measurement group_id="O2" value="-0.3" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 56, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.96"/>
                    <measurement group_id="O2" value="-0.4" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 20, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.83"/>
                    <measurement group_id="O2" value="-0.3" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 80, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.87"/>
                    <measurement group_id="O2" value="-2.1" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 56, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.81"/>
                    <measurement group_id="O2" value="-0.7" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 20, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.71"/>
                    <measurement group_id="O2" value="-0.4" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1260</p_value>
            <p_value_desc>Overall population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3117</p_value>
            <p_value_desc>Male population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1776</p_value>
            <p_value_desc>Female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2259</p_value>
            <p_value_desc>Premenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3840</p_value>
            <p_value_desc>postmenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Distal Radius BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
        <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Distal Radius BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
          <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall population, Week 80, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.63"/>
                    <measurement group_id="O2" value="-0.1" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 56, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.55"/>
                    <measurement group_id="O2" value="0.5" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 20, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.58"/>
                    <measurement group_id="O2" value="0.9" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 80, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.84"/>
                    <measurement group_id="O2" value="-0.6" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 56, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.73"/>
                    <measurement group_id="O2" value="0.4" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 20, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.75"/>
                    <measurement group_id="O2" value="0.2" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 80, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.00"/>
                    <measurement group_id="O2" value="0.1" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 56, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.87"/>
                    <measurement group_id="O2" value="0.7" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 20, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.94"/>
                    <measurement group_id="O2" value="1.1" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 80, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.51"/>
                    <measurement group_id="O2" value="-0.3" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 56, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.37"/>
                    <measurement group_id="O2" value="-0.6" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 20, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.51"/>
                    <measurement group_id="O2" value="0.7" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 80, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.61"/>
                    <measurement group_id="O2" value="-0.2" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 56, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.34"/>
                    <measurement group_id="O2" value="0.8" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 20, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.36"/>
                    <measurement group_id="O2" value="1.3" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6102</p_value>
            <p_value_desc>Overall population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3445</p_value>
            <p_value_desc>Male population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9735</p_value>
            <p_value_desc>Female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4861</p_value>
            <p_value_desc>Premenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8770</p_value>
            <p_value_desc>Postmenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
        <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body BMD at Weeks 20, 56, and 80 (Bone Sub-study Subset of Participants)</title>
          <description>BMD was measured by dual X-ray absorptiometry (DXA). The percent change from baseline in BMD at a given timepoint was defined at the participant level by the following formula: percent change = (BMD at given week minus BMD at baseline)/BMD at baseline x 100. This outcome measure was analyzed for a subset of participants in the bone study only.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BMD assessment(s) at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall population, Week 80, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.64"/>
                    <measurement group_id="O2" value="1.1" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 56, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.63"/>
                    <measurement group_id="O2" value="-0.1" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population, Week 20, n=87, 87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.37"/>
                    <measurement group_id="O2" value="0.5" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 80, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.43"/>
                    <measurement group_id="O2" value="0.5" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 56, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.41"/>
                    <measurement group_id="O2" value="0.5" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male population, Week 20, n=38, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.43"/>
                    <measurement group_id="O2" value="0.5" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 80, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.00"/>
                    <measurement group_id="O2" value="1.0" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 56, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.03"/>
                    <measurement group_id="O2" value="1.2" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female population, Week 20, n=49, 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.56"/>
                    <measurement group_id="O2" value="0.5" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 80, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.26"/>
                    <measurement group_id="O2" value="-0.2" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 56, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.42"/>
                    <measurement group_id="O2" value="-1.0" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal population, Week 20, n=21, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.38"/>
                    <measurement group_id="O2" value="0.3" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 80, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.56"/>
                    <measurement group_id="O2" value="-0.4" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 56, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.49"/>
                    <measurement group_id="O2" value="-0.6" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal population, Week 20, n=28, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.45"/>
                    <measurement group_id="O2" value="0.1" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7015</p_value>
            <p_value_desc>Overall population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6767</p_value>
            <p_value_desc>Male population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4199</p_value>
            <p_value_desc>Female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2526</p_value>
            <p_value_desc>Premenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.4</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4153</p_value>
            <p_value_desc>postmenopausal female population, Week 80. No adjustment for multiple comparisons. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Calcium at Weeks 12, 32, 56, and 80</title>
        <description>Blood was taken for measurement of serum calcium. Percent change from baseline was based on log transformed data. Geometric mean, GM; standard error, SE. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Weeks 12, 32, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with serum calcium measurements at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Calcium at Weeks 12, 32, 56, and 80</title>
          <description>Blood was taken for measurement of serum calcium. Percent change from baseline was based on log transformed data. Geometric mean, GM; standard error, SE. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with serum calcium measurements at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk80 % change + SE, overall n= 79, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.929"/>
                    <measurement group_id="O2" value="1.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, overall n=79, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.424"/>
                    <measurement group_id="O2" value="0.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, overall n= 79, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.079"/>
                    <measurement group_id="O2" value="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, overall n= 79, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.098"/>
                    <measurement group_id="O2" value="1.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, overall n= 79, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.527"/>
                    <measurement group_id="O2" value="0.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, overall n 79, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040"/>
                    <measurement group_id="O2" value="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change + SE, overall n=78, 77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.136"/>
                    <measurement group_id="O2" value="-0.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change, overall n= 78, 77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.316"/>
                    <measurement group_id="O2" value="-1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change - SE, overall n 78, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.766"/>
                    <measurement group_id="O2" value="-1.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change + SE, overall n=81, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.568"/>
                    <measurement group_id="O2" value="-0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change, overall n= 81, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.123"/>
                    <measurement group_id="O2" value="-0.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change - SE, overall n 81, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.320"/>
                    <measurement group_id="O2" value="-1.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, males n=34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8777"/>
                    <measurement group_id="O2" value="1.551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, males n= 34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.071"/>
                    <measurement group_id="O2" value="0.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, males n 34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.728"/>
                    <measurement group_id="O2" value="0.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, males n=34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.304"/>
                    <measurement group_id="O2" value="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, males n= 34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.646"/>
                    <measurement group_id="O2" value="0.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, males n 34, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009"/>
                    <measurement group_id="O2" value="-0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change + SE, males n=33, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.538"/>
                    <measurement group_id="O2" value="-0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change, males n= 33, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.281"/>
                    <measurement group_id="O2" value="-1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change - SE, males n 33,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.019"/>
                    <measurement group_id="O2" value="-1.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change + SE, males n=37, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.410"/>
                    <measurement group_id="O2" value="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change, males n= 37, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.656"/>
                    <measurement group_id="O2" value="-0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change - SE, males n 37, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091"/>
                    <measurement group_id="O2" value="-0.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, females n= 45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.508"/>
                    <measurement group_id="O2" value="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, females n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.735"/>
                    <measurement group_id="O2" value="0.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, females n= 45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033"/>
                    <measurement group_id="O2" value="-0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, females n= 45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.692"/>
                    <measurement group_id="O2" value="1.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, females n=45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.720"/>
                    <measurement group_id="O2" value="0.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, females n= 45, 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.242"/>
                    <measurement group_id="O2" value="-0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change + SE, females n= 45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.637"/>
                    <measurement group_id="O2" value="-0.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change, females n=45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038"/>
                    <measurement group_id="O2" value="-1.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change - SE, females n= 45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.557"/>
                    <measurement group_id="O2" value="-1.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change + SE, females n= 44, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.715"/>
                    <measurement group_id="O2" value="-0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change, females n=44, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055"/>
                    <measurement group_id="O2" value="-1.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change - SE, females n= 44, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.600"/>
                    <measurement group_id="O2" value="-1.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, premenopausal females n=19, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.429"/>
                    <measurement group_id="O2" value="0.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, premenopausal females n= 19, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.531"/>
                    <measurement group_id="O2" value="-0.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, premenopausal females n 19, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.359"/>
                    <measurement group_id="O2" value="-0.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, premenopausal females n=19, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.091"/>
                    <measurement group_id="O2" value="2.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, premenopausal females n= 19, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960"/>
                    <measurement group_id="O2" value="1.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, premenopausal females n 19, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.159"/>
                    <measurement group_id="O2" value="0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change + SE, premenopausal females n=19, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.074"/>
                    <measurement group_id="O2" value="-0.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change, premenopausal females n= 19, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.070"/>
                    <measurement group_id="O2" value="-1.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change - SE, premenopausal females n 19, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.923"/>
                    <measurement group_id="O2" value="-2.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change + SE, premenopausal females n=19, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.420"/>
                    <measurement group_id="O2" value="-0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change, premenopausal females n= 19, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.657"/>
                    <measurement group_id="O2" value="-1.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change - SE, premenopausal females n 19, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.722"/>
                    <measurement group_id="O2" value="-2.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change+ SE, postmenopausal females n=26, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.019"/>
                    <measurement group_id="O2" value="1.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, postmenopausal females n=26, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.760"/>
                    <measurement group_id="O2" value="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80% change - SE, postmenopausal females n=26, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.484"/>
                    <measurement group_id="O2" value="-0.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change+ SE, postmenopausal females n=26, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.181"/>
                    <measurement group_id="O2" value="2.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, postmenopausal females n=26, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.560"/>
                    <measurement group_id="O2" value="0.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56% change - SE, postmenopausal females n=26, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.035"/>
                    <measurement group_id="O2" value="-0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change+ SE, postmenopausal females n=26, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.844"/>
                    <measurement group_id="O2" value="-0.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32 % change, postmenopausal females n=26, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056"/>
                    <measurement group_id="O2" value="-1.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32% change - SE, postmenopausal females n=26, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.726"/>
                    <measurement group_id="O2" value="-2.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change+ SE, postmenopausal females n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.844"/>
                    <measurement group_id="O2" value="-1.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12 % change, postmenopausal females n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042"/>
                    <measurement group_id="O2" value="-2.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12% change - SE, postmenopausal females n=25, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.921"/>
                    <measurement group_id="O2" value="-2.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7895</p_value>
            <p_value_desc>Overall population, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>0.168</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.066</ci_lower_limit>
            <ci_upper_limit>1.417</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4155</p_value>
            <p_value_desc>Males, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>0.745</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.064</ci_lower_limit>
            <ci_upper_limit>2.587</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6223</p_value>
            <p_value_desc>Females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-0.452</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.253</ci_lower_limit>
            <ci_upper_limit>1.382</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5908</p_value>
            <p_value_desc>Premenopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-0.638</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.043</ci_lower_limit>
            <ci_upper_limit>1.826</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9154</p_value>
            <p_value_desc>Postmenopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-0.155</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.037</ci_lower_limit>
            <ci_upper_limit>2.814</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Intact Parathyroid Hormone at Week 80</title>
        <description>Blood was taken for measurement of intact parathyroid hormone. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with intact parathyroid hormone measurements at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Intact Parathyroid Hormone at Week 80</title>
          <description>Blood was taken for measurement of intact parathyroid hormone. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with intact parathyroid hormone measurements at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk80 % change + SE, overall n= 45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.296"/>
                    <measurement group_id="O2" value="0.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, overall n=45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.634"/>
                    <measurement group_id="O2" value="-6.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, overall n= 45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.565"/>
                    <measurement group_id="O2" value="-12.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, males n=16, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.160"/>
                    <measurement group_id="O2" value="-2.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, males n= 16, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.238"/>
                    <measurement group_id="O2" value="-8.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, males n=16, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.655"/>
                    <measurement group_id="O2" value="-14.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, females n= 30, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.662"/>
                    <measurement group_id="O2" value="11.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, females n=30, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.608"/>
                    <measurement group_id="O2" value="-1.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 80 % change - SE, females n= 30, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.056"/>
                    <measurement group_id="O2" value="-13.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, premenopausal females n=13, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.295"/>
                    <measurement group_id="O2" value="24.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, premenopausal females n= 13, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.686"/>
                    <measurement group_id="O2" value="-0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, premenopausal females n=13, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.440"/>
                    <measurement group_id="O2" value="-20.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change+ SE, postmenopausal females n=16, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.017"/>
                    <measurement group_id="O2" value="8.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, postmenopausal females n=16, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.109"/>
                    <measurement group_id="O2" value="-9.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80% change - SE, postmenopausal females n=16, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.014"/>
                    <measurement group_id="O2" value="-23.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8682</p_value>
            <p_value_desc>Overall population, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>1.467</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.785</ci_lower_limit>
            <ci_upper_limit>20.818</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9740</p_value>
            <p_value_desc>Males, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>0.328</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.308</ci_lower_limit>
            <ci_upper_limit>23.214</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8378</p_value>
            <p_value_desc>Females, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>2.986</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.997</ci_lower_limit>
            <ci_upper_limit>37.735</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7889</p_value>
            <p_value_desc>Pre-menopausal females, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>8.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.839</ci_lower_limit>
            <ci_upper_limit>108.422</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8800</p_value>
            <p_value_desc>Postmenopausal females, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>.Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>3.344</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.853</ci_lower_limit>
            <ci_upper_limit>63.935</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in 25-hydroxy Vitamin D at Week 80</title>
        <description>Blood was taken for measurement of 25-hydroxy vitamin D. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Week 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with 25-hydroxy vitamin D measurements at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in 25-hydroxy Vitamin D at Week 80</title>
          <description>Blood was taken for measurement of 25-hydroxy vitamin D. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with 25-hydroxy vitamin D measurements at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk80 % change + SE, overall n= 45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0053"/>
                    <measurement group_id="O2" value="-4.6305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, overall n=45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9678"/>
                    <measurement group_id="O2" value="-12.9210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 80 % change - SE, overall n= 45, 38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4091"/>
                    <measurement group_id="O2" value="-20.4909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, males n=16, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9639"/>
                    <measurement group_id="O2" value="-4.2837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, males n=16, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4369"/>
                    <measurement group_id="O2" value="-14.1507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, males n=16, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1896"/>
                    <measurement group_id="O2" value="-23.0005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, females n= 29, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1080"/>
                    <measurement group_id="O2" value="4.7124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, females n=29, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4578"/>
                    <measurement group_id="O2" value="-9.0412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 80 % change - SE, females n= 29, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8664"/>
                    <measurement group_id="O2" value="-20.9882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, premenopausal females n=13, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0833"/>
                    <measurement group_id="O2" value="0.3546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, premenopausal females n= 13, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3838"/>
                    <measurement group_id="O2" value="-16.2325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, premenopausal females n=13, 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8776"/>
                    <measurement group_id="O2" value="-30.0781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change+ SE, postmenopausal females n=16, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8368"/>
                    <measurement group_id="O2" value="17.3807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, postmenopausal females n=16, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1318"/>
                    <measurement group_id="O2" value="-2.7100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80% change - SE, postmenopausal females n=16, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7575"/>
                    <measurement group_id="O2" value="-19.3620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9069</p_value>
            <p_value_desc>Overall population, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>1.2168</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.6057</ci_lower_limit>
            <ci_upper_limit>24.3392</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5118</p_value>
            <p_value_desc>Males, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-10.1648</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.6298</ci_lower_limit>
            <ci_upper_limit>25.3742</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5816</p_value>
            <p_value_desc>Females, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>8.8777</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.2636</ci_lower_limit>
            <ci_upper_limit>48.6692</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9587</p_value>
            <p_value_desc>Pre-menopausal females, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-1.0031</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.9280</ci_lower_limit>
            <ci_upper_limit>52.9590</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8337</p_value>
            <p_value_desc>Postmenopausal females, Week 80. Log transformed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>4.7614</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.4741</ci_lower_limit>
            <ci_upper_limit>67.4901</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Estradiol at Weeks 20, 56, and 80</title>
        <description>Blood was taken for measurement of estradiol. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of female participants in the bone study only. n is the number of evaluable participants, which is the number of female participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with estradiol measurements at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Estradiol at Weeks 20, 56, and 80</title>
          <description>Blood was taken for measurement of estradiol. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of female participants in the bone study only. n is the number of evaluable participants, which is the number of female participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with estradiol measurements at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk80 % change + SE, females n= 30, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.695"/>
                    <measurement group_id="O2" value="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, females n=30, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.360"/>
                    <measurement group_id="O2" value="-15.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 80 % change - SE, females n= 30, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.268"/>
                    <measurement group_id="O2" value="-28.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, females n= 27, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.015"/>
                    <measurement group_id="O2" value="10.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, females n=27, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.815"/>
                    <measurement group_id="O2" value="-2.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 56 % change - SE, females n= 27, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.175"/>
                    <measurement group_id="O2" value="-13.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, females n= 36, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.863"/>
                    <measurement group_id="O2" value="14.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, females n=36, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.097"/>
                    <measurement group_id="O2" value="-0.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 20 % change - SE, females n= 36, 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.500"/>
                    <measurement group_id="O2" value="-14.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, premenopausal females n=13, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.386"/>
                    <measurement group_id="O2" value="67.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, premenopausal females n= 13, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.314"/>
                    <measurement group_id="O2" value="7.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, premenopausal females n=13, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.472"/>
                    <measurement group_id="O2" value="-30.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, premenopausal females n=12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.708"/>
                    <measurement group_id="O2" value="19.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, premenopausal females n= 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.677"/>
                    <measurement group_id="O2" value="-11.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, premenopausal females n=12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.820"/>
                    <measurement group_id="O2" value="-34.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, premenopausal females n=15, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.738"/>
                    <measurement group_id="O2" value="8.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, premenopausal females n=15, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.721"/>
                    <measurement group_id="O2" value="-3.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, premenopausal females n=15, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.334"/>
                    <measurement group_id="O2" value="-13.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change+ SE, postmenopausal females n=17, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.303"/>
                    <measurement group_id="O2" value="-25.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, postmenopausal females n=17, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.045"/>
                    <measurement group_id="O2" value="-31.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80% change - SE, postmenopausal females n=17, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.334"/>
                    <measurement group_id="O2" value="-37.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change+ SE, postmenopausal females n=15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.758"/>
                    <measurement group_id="O2" value="-18.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, postmenopausal females n=15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.766"/>
                    <measurement group_id="O2" value="-25.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56% change - SE, postmenopausal females n=15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.113"/>
                    <measurement group_id="O2" value="-31.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change+ SE, postmenopausal females n=21, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.432"/>
                    <measurement group_id="O2" value="16.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, postmenopausal females n=21, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.870"/>
                    <measurement group_id="O2" value="-5.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20% change - SE, postmenopausal females n=21, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.603"/>
                    <measurement group_id="O2" value="-22.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7041</p_value>
            <p_value_desc>Females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>7.527</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.773</ci_lower_limit>
            <ci_upper_limit>57.892</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6403</p_value>
            <p_value_desc>Pre-menopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>30.211</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.586</ci_lower_limit>
            <ci_upper_limit>341.371</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8474</p_value>
            <p_value_desc>Postmenopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>.Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline.</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>1.929</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.015</ci_lower_limit>
            <ci_upper_limit>25.198</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in C-terminal Telopeptide (CTX) at Weeks 20, 56, and 80</title>
        <description>Blood was taken for measurement of CTX. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with CTX measurements at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in C-terminal Telopeptide (CTX) at Weeks 20, 56, and 80</title>
          <description>Blood was taken for measurement of CTX. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with CTX measurements at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk80 % change + SE, overall n=69, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7"/>
                    <measurement group_id="O2" value="-7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, overall n=69, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7"/>
                    <measurement group_id="O2" value="-14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, overall n=79, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2"/>
                    <measurement group_id="O2" value="-20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, overall n=68, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, overall n=68, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4"/>
                    <measurement group_id="O2" value="-3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, overall n=68, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1"/>
                    <measurement group_id="O2" value="-9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, overall n=61, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8"/>
                    <measurement group_id="O2" value="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, overall n=61, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5"/>
                    <measurement group_id="O2" value="-5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, overall n=61, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9"/>
                    <measurement group_id="O2" value="-10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, males n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0"/>
                    <measurement group_id="O2" value="-1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, males n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7"/>
                    <measurement group_id="O2" value="-10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, males n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.2"/>
                    <measurement group_id="O2" value="-19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, males n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, males n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0"/>
                    <measurement group_id="O2" value="-2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, males n=28, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7"/>
                    <measurement group_id="O2" value="-10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, males n=23, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, males n=23, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, males n=23, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3"/>
                    <measurement group_id="O2" value="-1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, females n=41, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9"/>
                    <measurement group_id="O2" value="-8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, females n=41, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1"/>
                    <measurement group_id="O2" value="-16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, females n=41, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.6"/>
                    <measurement group_id="O2" value="-24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8"/>
                    <measurement group_id="O2" value="-8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5"/>
                    <measurement group_id="O2" value="-16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, females n=38, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5"/>
                    <measurement group_id="O2" value="-8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, females n=38, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9"/>
                    <measurement group_id="O2" value="-15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, females n=38, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0"/>
                    <measurement group_id="O2" value="-21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, premenopausal females n=18, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6"/>
                    <measurement group_id="O2" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, premenopausal females n=18, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8"/>
                    <measurement group_id="O2" value="-4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, premenopausal females n=18, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.0"/>
                    <measurement group_id="O2" value="-18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, premenopausal females n=18, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.5"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, premenopausal females n=18, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, premenopausal females n=18, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.5"/>
                    <measurement group_id="O2" value="-9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, premenopausal females n=16, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2"/>
                    <measurement group_id="O2" value="-7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, premenopausal females n=16, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0"/>
                    <measurement group_id="O2" value="-18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, premenopausal females n=16, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.8"/>
                    <measurement group_id="O2" value="-28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change+ SE, postmenopausal females n=23, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5"/>
                    <measurement group_id="O2" value="-14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, postmenopausal females n=23, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0"/>
                    <measurement group_id="O2" value="-24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80% change - SE, postmenopausal females n=23, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5"/>
                    <measurement group_id="O2" value="-33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change+ SE, postmenopausal females n=22, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, postmenopausal females n=22, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1"/>
                    <measurement group_id="O2" value="-7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56% change - SE, postmenopausal females n=22, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0"/>
                    <measurement group_id="O2" value="-18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change+ SE, postmenopausal females n=22, 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="-3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, postmenopausal females n=22, 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8"/>
                    <measurement group_id="O2" value="-13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20% change - SE, postmenopausal females n=22, 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7"/>
                    <measurement group_id="O2" value="-22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4860</p_value>
            <p_value_desc>Overall, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>23.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3791</p_value>
            <p_value_desc>Males, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>12.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>46.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7065</p_value>
            <p_value_desc>Females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.3</ci_lower_limit>
            <ci_upper_limit>27.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1381</p_value>
            <p_value_desc>Pre-menopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>32.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>92.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7195</p_value>
            <p_value_desc>Postmenopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>.Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.4</ci_lower_limit>
            <ci_upper_limit>22.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Procollagen Type-1 N-propeptide (P1NP) at Weeks 20, 56, and 80</title>
        <description>Blood was taken for measurement of P1NP. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with P1NP measurements at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Procollagen Type-1 N-propeptide (P1NP) at Weeks 20, 56, and 80</title>
          <description>Blood was taken for measurement of P1NP. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with P1NP measurements at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk80 % change + SE, overall n= 72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4"/>
                    <measurement group_id="O2" value="-20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.0"/>
                    <measurement group_id="O2" value="-24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.5"/>
                    <measurement group_id="O2" value="-27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5"/>
                    <measurement group_id="O2" value="-26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.9"/>
                    <measurement group_id="O2" value="-30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2"/>
                    <measurement group_id="O2" value="-33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, overall n=66, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.0"/>
                    <measurement group_id="O2" value="-31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, overall n=66, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.0"/>
                    <measurement group_id="O2" value="-34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, overall n=66, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.0"/>
                    <measurement group_id="O2" value="-37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.5"/>
                    <measurement group_id="O2" value="-18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1"/>
                    <measurement group_id="O2" value="-23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4"/>
                    <measurement group_id="O2" value="-28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7"/>
                    <measurement group_id="O2" value="-23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7"/>
                    <measurement group_id="O2" value="-27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4"/>
                    <measurement group_id="O2" value="-31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, males n=26, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.2"/>
                    <measurement group_id="O2" value="-24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, males n=26, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.4"/>
                    <measurement group_id="O2" value="-29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, males n=26, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3"/>
                    <measurement group_id="O2" value="-33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.3"/>
                    <measurement group_id="O2" value="-19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8"/>
                    <measurement group_id="O2" value="-24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.2"/>
                    <measurement group_id="O2" value="-29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6"/>
                    <measurement group_id="O2" value="-27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8"/>
                    <measurement group_id="O2" value="-32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.9"/>
                    <measurement group_id="O2" value="-36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.2"/>
                    <measurement group_id="O2" value="-31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.0"/>
                    <measurement group_id="O2" value="-36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.5"/>
                    <measurement group_id="O2" value="-41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9"/>
                    <measurement group_id="O2" value="-11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.6"/>
                    <measurement group_id="O2" value="-20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7"/>
                    <measurement group_id="O2" value="-28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.3"/>
                    <measurement group_id="O2" value="-23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.0"/>
                    <measurement group_id="O2" value="-30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.2"/>
                    <measurement group_id="O2" value="-37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, premenopausal females n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.6"/>
                    <measurement group_id="O2" value="-29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, premenopausal females n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.4"/>
                    <measurement group_id="O2" value="-36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, premenopausal females n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.7"/>
                    <measurement group_id="O2" value="-43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change+ SE, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5"/>
                    <measurement group_id="O2" value="-27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.4"/>
                    <measurement group_id="O2" value="-33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80% change - SE, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.8"/>
                    <measurement group_id="O2" value="-39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change+ SE, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1"/>
                    <measurement group_id="O2" value="-35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.9"/>
                    <measurement group_id="O2" value="-41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56% change - SE, postmenopausal females n=22, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.2"/>
                    <measurement group_id="O2" value="-47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change+ SE, postmenopausal females n=23, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.2"/>
                    <measurement group_id="O2" value="-34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, postmenopausal females n=23, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.9"/>
                    <measurement group_id="O2" value="-40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20% change - SE, postmenopausal females n=23, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.0"/>
                    <measurement group_id="O2" value="-47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5595</p_value>
            <p_value_desc>Overall, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.3</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9125</p_value>
            <p_value_desc>Males, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.3</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9122</p_value>
            <p_value_desc>Females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7435</p_value>
            <p_value_desc>Pre-menopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.2</ci_lower_limit>
            <ci_upper_limit>38.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3897</p_value>
            <p_value_desc>Postmenopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>.Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.0</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Alkaline Phosphatase (BSAP) at Weeks 20, 56, and 80</title>
        <description>Blood was taken for measurement of BSAP. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
        <time_frame>Baseline and Weeks 20, 56, and 80</time_frame>
        <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BSAP measurements at Week 20 or later were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
          </group>
          <group group_id="O2">
            <title>Avandamet</title>
            <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Alkaline Phosphatase (BSAP) at Weeks 20, 56, and 80</title>
          <description>Blood was taken for measurement of BSAP. Percent change from baseline was based on log transformed data. Standard error, SE; Wk, Week; %, percent. This outcome measure was analyzed for a subset of participants in the bone study only. n is the number of evaluable participants, which is the number of participants with a value at baseline and at the specified visit for the parameter of interest.</description>
          <population>Week 20 Evaluable for the Bone Sub-study Population. This is a subset of the bone sub-study with LOCF from Week 20. Only participants with BSAP measurements at Week 20 or later were included.</population>
          <units>percent change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk80 % change + SE, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.19"/>
                    <measurement group_id="O2" value="-23.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.23"/>
                    <measurement group_id="O2" value="-26.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.15"/>
                    <measurement group_id="O2" value="-29.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.29"/>
                    <measurement group_id="O2" value="-24.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.52"/>
                    <measurement group_id="O2" value="-27.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, overall n=72, 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.61"/>
                    <measurement group_id="O2" value="-30.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, overall n=66, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.16"/>
                    <measurement group_id="O2" value="-31.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, overall n=66, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.46"/>
                    <measurement group_id="O2" value="-33.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, overall n=66, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.70"/>
                    <measurement group_id="O2" value="-35.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.44"/>
                    <measurement group_id="O2" value="-21.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.35"/>
                    <measurement group_id="O2" value="-25.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.97"/>
                    <measurement group_id="O2" value="-29.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.22"/>
                    <measurement group_id="O2" value="-21.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.05"/>
                    <measurement group_id="O2" value="-25.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, males n=30, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.62"/>
                    <measurement group_id="O2" value="-29.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, males n=26, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.27"/>
                    <measurement group_id="O2" value="-26.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, males n=26, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.50"/>
                    <measurement group_id="O2" value="-30.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, males n=26, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.51"/>
                    <measurement group_id="O2" value="-33.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.30"/>
                    <measurement group_id="O2" value="-23.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.11"/>
                    <measurement group_id="O2" value="-27.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.74"/>
                    <measurement group_id="O2" value="-31.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.54"/>
                    <measurement group_id="O2" value="-24.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.75"/>
                    <measurement group_id="O2" value="-28.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, females n=42, 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.73"/>
                    <measurement group_id="O2" value="-33.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.82"/>
                    <measurement group_id="O2" value="-31.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.23"/>
                    <measurement group_id="O2" value="-35.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, females n=40, 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.48"/>
                    <measurement group_id="O2" value="-38.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change + SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.89"/>
                    <measurement group_id="O2" value="-23.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.28"/>
                    <measurement group_id="O2" value="-29.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change - SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.33"/>
                    <measurement group_id="O2" value="-35.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change + SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.43"/>
                    <measurement group_id="O2" value="-27.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.84"/>
                    <measurement group_id="O2" value="-32.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change - SE, premenopausal females n=19, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.02"/>
                    <measurement group_id="O2" value="-36.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change + SE, premenopausal females n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.73"/>
                    <measurement group_id="O2" value="-32.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, premenopausal females n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.57"/>
                    <measurement group_id="O2" value="-37.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change - SE, premenopausal females n=17, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.10"/>
                    <measurement group_id="O2" value="-42.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change+ SE, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.10"/>
                    <measurement group_id="O2" value="-25.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80 % change, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.39"/>
                    <measurement group_id="O2" value="-31.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk80% change - SE, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.29"/>
                    <measurement group_id="O2" value="-37.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change+ SE, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.51"/>
                    <measurement group_id="O2" value="-23.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56 % change, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.04"/>
                    <measurement group_id="O2" value="-31.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk56% change - SE, postmenopausal females n=23, 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.99"/>
                    <measurement group_id="O2" value="-38.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change+ SE, postmenopausal females n=23, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.14"/>
                    <measurement group_id="O2" value="-32.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20 % change, postmenopausal females n=23, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.70"/>
                    <measurement group_id="O2" value="-36.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20% change - SE, postmenopausal females n=23, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.97"/>
                    <measurement group_id="O2" value="-41.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5176</p_value>
            <p_value_desc>Overall, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-2.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.97</ci_lower_limit>
            <ci_upper_limit>6.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3620</p_value>
            <p_value_desc>Males, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-6.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.62</ci_lower_limit>
            <ci_upper_limit>7.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9115</p_value>
            <p_value_desc>Females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.39</ci_lower_limit>
            <ci_upper_limit>14.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1956</p_value>
            <p_value_desc>Pre-menopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>-13.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.35</ci_lower_limit>
            <ci_upper_limit>8.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6749</p_value>
            <p_value_desc>Postmenopausal females, Week 80. Log transformed. If the p value was significant at Week 80 a comparison was done at Week 56; if it was significant at Weeks 80 and 56, a comparison was done at Week 20.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>.Based on ANCOVA with terms for treatment, region, pre-screening HbA1c strata, sex, baseline</method_desc>
            <param_type>Percent difference from metformin</param_type>
            <param_value>3.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.09</ci_lower_limit>
            <ci_upper_limit>23.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>An on therapy adverse event (AE)/serious adverse event (SAE) was defined as an AE/SAE with onset on or after the start date of study medication but not later than two days after the last date of study medication.</time_frame>
      <desc>SAEs and AEs were collected in the Safety Population, comprised of all participants who were randomized and received at least one dose of the study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Beginning dose of Metformin (MET) 500 milligrams (mg) once a day. Dose could be increased up to a maximum dose of MET 2000 mg.</description>
        </group>
        <group group_id="E2">
          <title>Avandamet</title>
          <description>Beginning dose of Avandamet (AVM) 4 mg/500 mg once a day. Dose could be increased up to a maximum dose of 8 mg/2000 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Localized infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intrevertebral disc protusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nasal sinus cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cranial neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Haemorrhage itracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratort tract infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Ten participants who started the study and were randomized did not receive any study medication (6 participants in the metformin arm and 4 participants in the avandamet arm). These participants are not included in any of the analysis populations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

